Management Policies
Message from Leadership
Net sales, operating profit, and profit attributable to owners of the parent all reached record highs.
Sales increased in all regions, with China and AP region posting double-digit growth.
Operating profit expanded, despite the impact of inflation, due to increased gross profit on higher net sales.
May 2024
Kaoru Asano
President
President
In the fiscal year ended March 31, 2024, sales increased in all regions. Growth was particularly strong in China, where we are transitioning to local production, and emerging markets. Higher net sales pushed up gross profit, which lifted operating profit, despite the impact of inflation.
For the year, net sales was up 12.4% year on year, operating profit increased 6.4％, and profit attributable to owners of the parent expanded 8.4%—all of which were historic highs. At the exchange rates prevailing one year earlier, net sales would have been up 7.3%, and operating profit down 5.4%.
For the year, net sales was up 12.4% year on year, operating profit increased 6.4％, and profit attributable to owners of the parent expanded 8.4%—all of which were historic highs. At the exchange rates prevailing one year earlier, net sales would have been up 7.3%, and operating profit down 5.4%.
In the diagnostics business, sales in China grew thanks to ongoing efforts to transition to the local production of hematology*1 instruments, and the installed instrument base expanded in multiple fields in various regions. Sales of urinalysis, hemostasis, and immunochemistry reagents rose as a result. In the medical robotics business, the market responded favorably to an upgraded model of our hinotori™ surgical robot system, and we installed 20 units in the year ended March 31. The number of surgeries performed is increasing steadily; to date, the system has been used in 4,225 cases. Having receive approval for the system’s use in respiratory surgery, we expect the number of cases to increase further this fiscal year.
In the fiscal year ending March 31, 2025, we forecast net sales of ¥510.0 billion, operating profit of ¥87.0 billion, and profit attributable to owners of the parent of ¥55.0 billion.*2 We expect to pay annual dividends of ¥30 per share, up ¥2 per share. (This amounts to an increase of ¥6 per share, based on calculations prior to the stock split.)
In the fiscal year ending March 31, 2025, we forecast net sales of ¥510.0 billion, operating profit of ¥87.0 billion, and profit attributable to owners of the parent of ¥55.0 billion.*2 We expect to pay annual dividends of ¥30 per share, up ¥2 per share. (This amounts to an increase of ¥6 per share, based on calculations prior to the stock split.)
I would like to ask our stakeholders for your continued support.
For details, please see our results presentation for the fiscal year ended March 31, 2024 (Link).
For details, please see our results presentation for the fiscal year ended March 31, 2024 (Link).
*1 Hematology field: The field of in vitro diagnostics that determines whether precise testing is necessary by analyzing the number, type and size of red, white and other blood cells.
*2 Assumed exchange rates: USD1.00=JPY144.6, EUR1.00=JPY144.6, CNY1.00=JPY20.1
- For more information please see the materials below.
- Financial Reports & Presentations